Studies Shed New Light on Estrogen Receptor-Positive Breast Cancer
Nearly 80% of breast cancer are estrogen receptor-positive and endocrine therapy resistance occurs in approximately 30% of them.1 Researchers...
Potential New Targets to Treat Acute Myeloid Leukemia
Researchers have discovered new therapeutic targets for acute myeloid leukemia (AML). A new study published in Stem Cells suggests...
Positive Phase 3 trial results for an atopic dermatitis therapy
Atopic dermatitis, often called eczema, affects people of all ages. It is a chronic inflammatory skin condition 1 that...
Panelist Diaries: What makes a good endpoint in cancer management?
In Plato’s book, The Theaetetus, Socrates was at wrestling school, discussing what he believed ‘knowledge’ to be to his...
A checkpoint inhibitor gains FDA approval in endometrial cancer
On April 22, 2021, the US Food and Drug Administration (FDA) granted Accelerated Approval to dostarlimab (Jemperli, GlaxoSmithKline) as...
Recent developments in primary hyperoxaluria treatment
Primary hyperoxaluria (PH) is a rare genetic disease in which high levels of oxalate are produced and can deposit...
Cancer vaccines in the clinic and in trials
Most vaccines are given as prophylactics, agents that protect healthy individuals before exposure to a pathogen. By contrast, therapeutic...
FDA Approves First Trial of CRISPR for Sickle Cell Disease
The U.S Food and Drug Administration (FDA) has approved the first clinical trial of CRISPR to correct sickle cell...
First-in-class drug approved for bone marrow protection during chemotherapy
Chemotherapy can be lifesaving, but it can also damage bone marrow and cause blood cell counts to drop, sometimes...
Exon-skipping drug approved for the third subtype of Duchenne muscular dystrophy
Discovering treatments for Duchenne muscular dystrophy has been difficult because the disease is a result of a wide variety...